SomaLogic Licenses GNS Healthcare’s REFS™ technology for analysis of its SOMAscan®- derived proteomic data
Combining the world-leading proteomic and artificial intelligence/machine learning technologies to produce novel, actionable health insights across many diseases, conditions and markets July 17, 2018 – SomaLogic and GNS Healthcare announced today that SomaLogic has obtained a license to apply GNS Healthcare’s proprietary REFS™ (Reverse Engineering & Forward Simulation) causal machine learning technology to SomaLogic’s proprietary SOMAscan®-derived protein data […]
GNS Healthcare Featured in Harvard Business Review Article on AI in the Workplace
GNS Healthcare is featured in the July/August issue of the Harvard Business Review as part of the article “Collaborative Intelligence: Humans and AI are Joining Forces”, a discussion of new digital tools and how AI can complement and augment human capabilities rather than replace humans in the work force. Colin Hill, CEO and Co-Founder, comments on […]
GNS Healthcare to Present Results on Prediction of Disease Progression Using AI in NASH Patients at The International Liver Congress™
CAMBRIDGE, Mass.– April 13, 2018– GNS Healthcare (GNS), a leading precision medicine company, will present results from a recent study on Friday, April 13th at the International Liver Congress™ 2018 in Paris. The analysis focused on the progression of Nonalcoholic Steatohepatitis (NASH), a type of advanced liver disease. Specifically, the objective was to build predictive models […]
Colin Hill featured in STAT News Article on Patient Data
March 29, 2018 – In early March, the Centers for Medicare and Medicaid Services (CMS) announced two initiatives, MyHealthEData and Blue Button 2.0, which aims to improve the control that patients have over their health data. In a recent STAT News article, GNS Chairman, CEO, and Co-Founder Colin Hill spoke with reporter Casey Ross on the value […]
GNS Board Member Dr. Adrian Weller appointed as Programme Director for Artificial Intelligence at The Alan Turing Institute
Today, The Alan Turing Institute announced the appointment of Dr. Adrian Weller as Programme Director for Artificial Intelligence. The Institute, named in honor of Alan Turing and based in London, aims to make great leaps in data science research in order to change the world for the better. His role will enable the Institute to […]
Roche Precision Medicine Article Features Iya Khalil
Dr. Iya Khalil, GNS chief commercial officer and co-founder, gave her perspectives on the application of machine learning to clinical trials in “Partnering in the Digital Era“, an article published by Roche this week. The precision medicine piece focuses on how collaborations between healthcare and technology companies are driving the future of healthcare and features […]
GNS Healthcare Uses Causal AI to Discover Which Multiple Myeloma Patients Will Have Progression Free Survival Benefit from Stem Cell Treatments
Details of the Discovery Leveraging the Multiple Myeloma Research Foundation CoMMpass Study Presented at 59th Annual ASH Meeting CAMBRIDGE, Mass.– December 12, 2017 – GNS Healthcare (GNS), a leading precision medicine company, together with the Multiple Myeloma Research Foundation (MMRF), have discovered a biomarker that identifies which multiple myeloma patients will benefit from stem cell transplantation. […]
Genentech oncology collaboration with GNS featured in TechEmergence
October 11, 2017 by Jon Walker Genentech, a member of the Roche Group, this summer announced their own collaboration with Cambridge, MA-based GNS Healthcare. GNS Healthcare’s mission statement is to use the latest innovations in machine learning to turn biomedical data into solutions and treatments. This collaboration’s first focus will also be on oncology, just like the IBM/Pfizer deal. Genentech […]
GenomeWeb Features GNS Healthcare’s Novel Parkinson’s Gene Discovery
Recently published research powered by GNS Healthcare, maker of a causal machine-learning platform for precision medicine, promises to unravel some of the mysteries of Parkinson’s disease, specifically the rate of progression of the neurodegenerative condition. Being able to use these [novel] predictors in the clinical setting will lead to faster and significantly cheaper clinical trials and […]
BioCentury highlights GNS-Alexion partnership
Alexion rebuilding pipeline with big data deals August 10, 2017 – Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) is rebuilding its early stage pipeline with two new deals focused on driving rare disease discovery with big genomic data. The company partnered with Sema4 (New York, N.Y.) for genomic sequencing and licensed the Reverse Engineering and Forward Simulation (REFS) […]